Paul Laikind is the CEO of ViaCyte, a San Diego company flying high with a recent $80 million Series D round. Photo courtesy of ViaCyte

Paul Laikind is the CEO of ViaCyte, a San Diego company flying high with a recent $80 million Series D round. Photo courtesy of ViaCyte

ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129